Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
International Journal of Molecular Sciences · 07.11.2023 · 24 (22) · 16056
DOI: 10.3390/ijms242216056 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.11.2023. Verfasst von Weiliang Zhuang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan R…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Antibodies, Bispecific, Immunoconjugates. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 (HER2) is considered an ideal antibody–drug conjugate (ADC) target because the gene is overexpressed in many tumors compared to normal tissues. Multiple anti-HER2 ADCs conjugated with different toxic payloads bring benefits to patients with high HER2 expression. However, HER2-targeted ADC technology needs further optimization to improve its effect for the treatment of patients with low HER2 expression. We hypothesized that bispecific antibody–drug conjugate (bsADC) targeting HER2 and Sortilin-1 (SORT1) would overcome this limitation. SORT1 is a suitable target for pairing with HER2 to generate a bispecific antibody (BsAb) since the gene is co-expressed with HER2 in tumors and possesses rapid internalization. We developed a BsAb (bsSORT1×HER2) that exhibited strong binding and internalization activity on HER2-low-expression tumor cells and facilitated higher HER2 degradation. The bsSORT1×HER2 was further conjugated with DXd to generate a bsADC (bsSORT1×HER2-DXd) that showed strong cytotoxicity on HER2-low-expression tumor cells and antitumor efficacy in an MDA-MB-231 xenograft mice model. These results demonstrated that employment of a SORT1×HER2-targeted bsADC may be promising to improve the antitumor efficacy of HER2-targeted ADC for the treatment of tumors with low HER2 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China.
- China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, China.
ORCID-Profile: Lei Wang, Baohong Zhang
Zitieren
APA
Zhuang, W., Zhang, W., Wang, L., Xie, L., Feng, J., Zhang, B., & Hu, Y. (2023). Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor. International Journal of Molecular Sciences, 24(22), 16056. https://doi.org/10.3390/ijms242216056
Vancouver
Zhuang W, Zhang W, Wang L, Xie L, Feng J, Zhang B, et al. Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor. International Journal of Molecular Sciences. 2023;24(22):16056. doi:10.3390/ijms242216056
BibTeX
@article{Zhuang2023,
author = {Zhuang, Weiliang and Zhang, Wei and Wang, Lei and Xie, Liping and Feng, Jun and Zhang, Baohong and Hu, Youjia},
title = {Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {22},
pages = {16056},
doi = {10.3390/ijms242216056}
}
EUVIMED